Genmab A/S (NASDAQ:GMAB) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Genmab A/S (NASDAQ:GMAB) have been assigned a consensus rating of “Moderate Buy” from the twelve ratings firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and nine have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $45.20.

Several equities research analysts have weighed in on the company. Morgan Stanley restated an “equal weight” rating and set a $31.00 target price on shares of Genmab A/S in a research note on Wednesday, September 11th. Truist Financial dropped their price objective on Genmab A/S from $53.00 to $50.00 and set a “buy” rating for the company in a research report on Monday, September 9th. Royal Bank of Canada upgraded Genmab A/S from a “sector perform” rating to an “outperform” rating in a research report on Monday, July 15th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Genmab A/S in a report on Tuesday, August 20th. Finally, HC Wainwright restated a “buy” rating and issued a $50.00 price target on shares of Genmab A/S in a research note on Wednesday, October 16th.

Genmab A/S Stock Performance

Shares of NASDAQ GMAB opened at $22.78 on Thursday. The stock has a market capitalization of $15.08 billion, a P/E ratio of 18.83, a PEG ratio of 0.66 and a beta of 0.99. The stock’s fifty day moving average is $24.78 and its 200 day moving average is $26.54. Genmab A/S has a 52 week low of $22.22 and a 52 week high of $32.89.

Genmab A/S (NASDAQ:GMAB) last issued its earnings results on Thursday, August 8th. The company reported $0.22 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.07). Genmab A/S had a net margin of 29.06% and a return on equity of 17.48%. The firm had revenue of $779.50 million during the quarter, compared to analyst estimates of $734.60 million. Equities research analysts forecast that Genmab A/S will post 1.29 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC increased its position in Genmab A/S by 360.5% in the 1st quarter. SG Americas Securities LLC now owns 29,500 shares of the company’s stock valued at $882,000 after acquiring an additional 23,094 shares during the period. Capital International Investors raised its position in Genmab A/S by 7.8% during the 1st quarter. Capital International Investors now owns 4,373,277 shares of the company’s stock worth $130,805,000 after purchasing an additional 315,355 shares during the last quarter. Oppenheimer Asset Management Inc. lifted its holdings in Genmab A/S by 26.3% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 218,078 shares of the company’s stock worth $5,480,000 after buying an additional 45,376 shares during the period. Choreo LLC bought a new stake in shares of Genmab A/S in the 2nd quarter valued at about $776,000. Finally, Renaissance Technologies LLC grew its position in shares of Genmab A/S by 7.6% in the 2nd quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock valued at $36,752,000 after buying an additional 103,859 shares during the last quarter. Institutional investors own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.